The FDA has sent both Teva Pharmaceuticals and France-based MedinCell a Complete Response Letter regarding their joint new drug application (NDA) for TV-46000/mdc-IRM, their extended-release formulation of risperidone for the treatment of patients with schizophrenia.
Source: Drug Industry Daily